RVPH (Reviva Pharmaceuticals Holdings) ROE % Adjusted to Book Value: -181.50% (As of Mar. 2026)


RVPH Reviva Pharmaceuticals Holdings Inc RVPH
26 GF Score
Price $0.65
! 1 Warning Sign
View Full Analysis

What is Reviva Pharmaceuticals Holdings ROE % Adjusted to Book Value?

Reviva Pharmaceuticals Holdings RVPH -3.10% 26 ROE % Adjusted to Book Value is -181.50% as of Mar. 2026. GuruFocus rates RVPH with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Reviva Pharmaceuticals Holdings's ROE % for the quarter that ended in Mar. 2026 was -98.01%. Reviva Pharmaceuticals Holdings's PB Ratio for the quarter that ended in Mar. 2026 was 0.54. Reviva Pharmaceuticals Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -181.50%.

Reviva Pharmaceuticals Holdings ROE % Adjusted to Book Value Related Terms

Reviva Pharmaceuticals Holdings ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Reviva Pharmaceuticals Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Reviva Pharmaceuticals Holdings ROE % Adjusted to Book Value Chart

Reviva Pharmaceuticals Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -34.42 -14.73 -22.13 -8.83 -110.80

Reviva Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -100.56 -53.87 -181.50

RVPH vs AIM, BOLT, BRTX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reviva Pharmaceuticals Holdings ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Reviva Pharmaceuticals Holdings's ROE % Adjusted to Book Value falls into.


RVPH
26GF Score
Reviva Pharmaceuticals Holdings Inc RVPH
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Reviva Pharmaceuticals Holdings ROE % Adjusted to Book Value Calculation

Reviva Pharmaceuticals Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-419.93% / 3.79
=-110.80%

Reviva Pharmaceuticals Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-98.01% / 0.54
=-181.50%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -181.50% mean?
Reviva Pharmaceuticals Holdings (RVPH) has a ROE % Adjusted to Book Value of -181.50% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Reviva Pharmaceuticals Holdings and its competitors.
Is Reviva Pharmaceuticals Holdings' ROE % Adjusted to Book Value too high?
Reviva Pharmaceuticals Holdings' current ROE % Adjusted to Book Value is -181.50%. Overall, Reviva Pharmaceuticals Holdings has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Reviva Pharmaceuticals Holdings' ROE % Adjusted to Book Value compare to AIM and BOLT?
Reviva Pharmaceuticals Holdings' ROE % Adjusted to Book Value of -181.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Reviva Pharmaceuticals Holdings and its competitors. Reviva Pharmaceuticals Holdings's current ROE % Adjusted to Book Value is -181.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reviva Pharmaceuticals Holdings stock overvalued right now?
Reviva Pharmaceuticals Holdings (RVPH) has a current ROE % Adjusted to Book Value of -181.50%. The current ROE % Adjusted to Book Value is -181.50%. Reviva Pharmaceuticals Holdings' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Reviva Pharmaceuticals Holdings (RVPH), the current ROE % Adjusted to Book Value is -181.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Reviva Pharmaceuticals Holdings Business Description

Address 10080 North Wolfe Road, Suite SW3-200, Cupertino, CA, USA, 95014
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
26GF Score

Get the complete analysis for RVPH

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price